Drug
Afm13
Afm13: highest development phase Phase 2, developed by Affimed. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Affimed
Trials
| Drug | Phase | Indication |
|---|---|---|
| AFM13 NCT02321592 | Phase 2 | Hodgkin Lymphoma |
| AFM13 NCT05883449 | Phase 2 | Relapsed or Refractory Hodgkin Lymphoma |
| AFM13 NCT04101331 | Phase 2 | Peripheral T Cell Lymphoma |
| AFM13 NCT02665650 | Phase 1 | Hodgkin Lymphoma |
Latest
No recent events.
Follow Afm13 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.